The GLP-1 receptor agonist liraglutide has been approved for the treatment of T2DM at a dose of 1.8 mg daily and for chronic weight management at a dose of 3.0 mg daily [113]. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.